Your browser doesn't support javascript.
loading
Understanding the economic burden of chronic cough: a systematic literature review.
Bali, Vishal; Adriano, Ada; Byrne, Aidan; Akers, Katherine G; Frederickson, Andrew; Schelfhout, Jonathan.
Afiliação
  • Bali V; Center for Observational and Real-World Evidence (CORE), Merck & Co., Inc, Rahway, NJ, USA. vishal.bali@merck.com.
  • Adriano A; Merck Sharp & Dohme Corp, 2000 Galloping Hill Road, Kenilworth, NJ, 07033, US. vishal.bali@merck.com.
  • Byrne A; Outcomes research, MSD, London, UK.
  • Akers KG; Outcomes research, MSD, London, UK.
  • Frederickson A; PRECISIONheor, New York, NY, USA.
  • Schelfhout J; PRECISIONheor, New York, NY, USA.
BMC Pulm Med ; 23(1): 416, 2023 Oct 31.
Article em En | MEDLINE | ID: mdl-37907889
Chronic cough (CC) is associated with high healthcare resource utilization (HCRU) due to challenges in diagnosis and treatment and is anticipated to have a substantial economic impact. This systematic literature review (SLR) sought to identify evidence on the cost-effectiveness of treatments and the economic burden associated with CC. Electronic database searches were supplemented with searches of conference proceedings and health technology assessment body websites. Two independent reviewers assessed all citations for inclusion based on predefined inclusion/exclusion criteria. Key inclusion criteria were patient population with CC, and outcomes related to cost-effectiveness and HCRU and costs. After screening, one cost-effectiveness analysis was identified, alongside eight studies reporting HCRU and costs related to CC. Though evidence was limited, studies suggest that patients with CC incur higher costs and use more resources than those with acute cough. Types of resource use reported included healthcare contacts and prescriptions, diagnostic tests, referrals and specialist evaluations, and treatment use. There is a paucity of literature on HCRU and costs in CC, and very limited cost-effectiveness analyses. The economic burden appears higher in these patients however, without direct comparison to the general population it is difficult to determine the total impact. The increased burden is expected to be a result of the challenges with diagnosis and lack of approved treatments. However, limited conclusions can be drawn in the absence of further data. Future studies should endeavor to quantify the HCRU and cost attributable to patients with CC.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tosse / Estresse Financeiro Tipo de estudo: Systematic_reviews Limite: Humans Idioma: En Revista: BMC Pulm Med Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tosse / Estresse Financeiro Tipo de estudo: Systematic_reviews Limite: Humans Idioma: En Revista: BMC Pulm Med Ano de publicação: 2023 Tipo de documento: Article